We are live on ! Find out more
GPCR icon

Structure Therapeutics

156 hedge funds and large institutions have $1.58B invested in Structure Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $30.2M | Put options by funds: $19.7M

40% more capital invested

Capital invested by funds: $1.13B → $1.58B (+$449M)

21% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 48

3.03% more ownership

Funds ownership: 95.31%98.33% (+3%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

9% less funds holding

Funds holding: 172156 (-16)

41% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 37

Holders
156
Holders Change
-16
Holders Change %
-9.3%
% of All Funds
2.05%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
22
Increased
58
Reduced
48
Closed
37
Calls
$30.2M
Puts
$19.7M
Net Calls
+$10.6M
Net Calls Change
+$8.63M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$159M -$23.6M -1,186,582 -17%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$147M +$6.68M +335,403 +7%
ACA
3
Avoro Capital Advisors
New York
$144M +$103M +5,155,555 New
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$125M -$2.47M -124,180 -3%
DTC
5
Deep Track Capital
Connecticut
$118M -$18.3M -918,106 -18%
BI
6
BVF Inc
California
$89.7M +$28.5M +1,432,500 +81%
BBA
7
Baker Bros. Advisors
New York
$43.6M -$19M -952,658 -38%
CC
8
Casdin Capital
New York
$43.5M +$6.57M +330,000 +27%
RCM
9
RA Capital Management
Massachusetts
$42.5M
Millennium Management
10
Millennium Management
New York
$35.7M +$1.09M +54,496 +4%
Ameriprise
11
Ameriprise
Minnesota
$34.3M -$7.25M -364,054 -23%
O
12
OrbiMed
New York
$31.9M -$1.2M -60,000 -5%
TCM
13
TCG Crossover Management
California
$29.8M
SL
14
Siren LLC
Connecticut
$28.8M +$20.5M +1,026,811 New
RSCM
15
Rock Springs Capital Management
Maryland
$26.6M -$3.68M -184,725 -16%
DCM
16
Driehaus Capital Management
Illinois
$24.5M +$4M +200,712 +30%
LGM
17
Logos Global Management
California
$23.8M
Principal Financial Group
18
Principal Financial Group
Iowa
$22M -$1.31M -65,718 -8%
Franklin Resources
19
Franklin Resources
California
$20.9M +$78.7K +3,951 +0.5%
PHAM
20
Pacific Heights Asset Management
California
$19.6M +$4.78M +240,000 +52%
CCM
21
Catalio Capital Management
New York
$18.3M -$374K -18,765 -3%
Aberdeen Group
22
Aberdeen Group
United Kingdom
$16.4M +$3.69M +185,245 +46%
Morgan Stanley
23
Morgan Stanley
New York
$16.2M -$6.76M -339,605 -37%
Goldman Sachs
24
Goldman Sachs
New York
$14.1M +$5.66M +284,222 +129%
American Century Companies
25
American Century Companies
Missouri
$13.6M -$87.8K -4,407 -0.9%

GPCR Hedge Fund Activity: Q3 2025 in Review

156 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q3 2025, worth a combined $1.58B — up 40% from $1.13B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of GPCR and 22 opened new positions — a net loss of 15 holders — while 48 trimmed existing stakes and 58 added.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $103M. The largest seller was Capital International Investors, exiting entirely with an estimated $33.6M sold.

  • 156 institutional investors held Structure Therapeutics (GPCR) as of Q3 2025, down from 172 in Q2 2025.
  • Funds reported $1.58B of Structure Therapeutics stock for Q3 2025, up 40% quarter-over-quarter.
  • 22 funds opened new Structure Therapeutics positions in Q3 2025 and 37 closed out, a net change of -15 holders.
  • The largest Structure Therapeutics buyer in Q3 2025 was Avoro Capital Advisors, an estimated $103M added.
  • The largest Structure Therapeutics seller in Q3 2025 was Capital International Investors, an estimated $33.6M sold.

Based on aggregated 13F filings for Q3 2025.